Corcept Therapeutics Incorporated (CORT) vs Madrigal Pharmaceuticals, Inc. (MDGL)
- Corcept Therapeutics Incorporated CORT 110.16 −2.83%
- Madrigal Pharmaceuticals, Inc. MDGL 449.74 −2.19%
Corcept Therapeutics Incorporated and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. Corcept Therapeutics Incorporated is the larger, with a market value of $12.3B against $10.6B — 1.2× the size. Madrigal Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Corcept Therapeutics Incorporated trades at 212×. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against 16.0%. Corcept Therapeutics Incorporated has the higher net margin (6.53% vs −25.3%) and the higher return on invested capital (1.01% vs −787.3%). Across the 18 metrics below, Corcept Therapeutics Incorporated leads on 12 and Madrigal Pharmaceuticals, Inc. on 6.
Valuation
Profitability
| Metric | CORT | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.30% | 91.48% | 65.16% |
| Operating margin | 0.77% | (25.13%) | 0.00% |
| Net margin | 6.53% | (25.32%) | 0.00% |
| Free cash flow margin | 12.87% | (16.07%) | 0.00% |
| Return on equity | 8.08% | (53.31%) | (56.36%) |
| Return on assets | 6.41% | (28.77%) | (48.04%) |
| Return on invested capital | 1.01% | (787.33%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack